Abstract
Although cancer has long been considered a genetic disease, increasing evidence shows that epigenetic aberrations play a crucial role in affecting tumor biology and therapeutic response. The dysregulated epigenome in cancer cells reprograms the immune landscape within the tumor microenvironment, thereby hindering antitumor immunity, promoting tumor progression, and inducing immunotherapy resistance. Targeting epigenetically mediated tumor-immune crosstalk is an emerging strategy to inhibit tumor progression and circumvent the limitations of current immunotherapies, including immune checkpoint inhibitors. In this Review, we discuss the mechanisms by which epigenetic aberrations regulate tumor-immune interactions and how epigenetically targeted therapies inhibit tumor progression and synergize with immunotherapy.
| Original language | English (US) |
|---|---|
| Article number | e178540 |
| Journal | Journal of Clinical Investigation |
| Volume | 134 |
| Issue number | 12 |
| DOIs | |
| State | Published - Jun 17 2024 |
Funding
Authorship note: LP and FZ contributed equally to this work and are co\u2013first authors. Conflict of interest: ABH serves on the advisory boards of Caris Life Sciences and WCG Oncology; is supported by research grants from Alnylam and AbbVie; and receives consulting fees from Novocure and Istari Oncology. Additionally, she has active granted patents (no. 9,675,633, no. 9,399,662) and a pending patent (international applications PCT/US2022/019435 and US 63/158,642). Copyright: \u00A9 2024, Pang et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License. Reference information: J Clin Invest. 2024;134(12):e178540. https://doi.org/10.1172/JCI178540. This work was supported in part by NIH grant R01 NS124594 (to PC), NIH grant R01 NS127824 (to PC), and Department of Defense Career Development Award W81XWH-21-1-0380 (to PC).
ASJC Scopus subject areas
- General Medicine
